Blood test detects when hormone treatment for breast cancer stops working

November 11, 2015
Breast cancer patients with mutations in the estrogen receptor gene ESR1 are known to develop resistance to hormone therapy. A new study finds that resistance to hormone therapy usually evolves in the advanced stage of disease, suggesting that earlier treatment may help some patients avoid drug resistance. Credit: C. Bickel / Science Translational Medicine

Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.

The test gives an early warning of resistance to aromatase inhibitors, which are used to treat women with oestrogen receptor (ER)-positive , the most common kind.

A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust found that the test could detect mutations to the oestrogen receptor gene ESR1 - which conveys resistance to hormone - specifically in women treated with aromatase inhibitors.

Detecting mutations in this gene from DNA in the bloodstream could allow doctors to rapidly identify which patients are no longer benefiting from treatment and switch them to an alternative drug.

The work is published in the journal Science Translational Medicine today (Wednesday), and was funded by several organisations including the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (ICR), Breast Cancer Now, The Cridlan Ross Smith Charitable Trust and Cancer Research UK.

Researchers initially took blood samples from 171 women with ER-positive breast cancer, and then validated their results in three independent groups of patients.

They found that ESR1 mutations could be detected by an ultra-sensitive method known as multiplexed digital PCR analysis, which can read the genetic code of tiny amounts of DNA released by tumours.

This method proved able to detect DNA errors as sensitively as tumour biopsies, with 97 per cent matching between the two methods, and could in future remove the need for such an invasive procedure.

Researchers at the ICR and The Royal Marsden found that once ESR1 mutations were detected, mutated cancer cells multiplied and became the dominant type in the body - driving the disease to become more aggressive and progress rapidly.

Women who had breast cancers with ESR1 mutations were three times more likely to progress than those without.

The stage at which the cancer was treated had a huge influence over how cancers became resistant to aromatase inhibitors, which are used as standard after surgery in postmenopausal women with ER-positive breast cancer. Mutations in ESR1 only occurred in 6 per cent of patients first treated with when their cancers had not spread, but in 36 per of patients when the disease had already spread round the body by the time the drugs were administered. The research suggests more advanced cancers evolve drug resistance much more readily, reinforcing the importance of early diagnosis and early treatment for cancer.

Study leader Dr Nicholas Turner, Team Leader in Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

"Looking for cancer DNA in the blood allows us to analyse the genetic changes in cancer cells without the need for invasive biopsies. Our study demonstrates how these so-called liquid biopsies can be used to track the progress of treatment in the most common type of breast cancer.

"The test could give doctors an early warning of treatment failure and, as clinical trials of drugs that target ESR1 mutations are developed, help select the most appropriate treatment for women with advanced cancer."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: "We are in a new era of personalised cancer medicine, and liquid biopsies offer the hope that treatment can be monitored and adapted according to the evolution of an individual patient's cancer.

"In the space of the last couple of years there has been astonishingly rapid progress in the development of liquid biopsies to detect specific cancer in the bloodstream. I am excited by the prospects of these new tests and would like to see them assessed in clinical trials as soon as possible, so we can show that their use to adapt treatment can offer real benefits for cancer patients."

Explore further: New 'mutation-tracking' blood test could predict breast cancer relapse months in advance

More information: "Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer," by G. Schiavon et al. … scitranslmed.aac7551

Related Stories

New 'mutation-tracking' blood test could predict breast cancer relapse months in advance

August 26, 2015
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.

Landmark clinical trial shows gene-targeted drug can treat prostate cancer

October 28, 2015
A pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer, a major new clinical trial concludes.

Blood test picks out prostate cancer drug resistance

November 4, 2015
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.

Blood test could match cancer patients to best treatments

October 15, 2015
UK-funded scientists have developed a blood test that could help pair cancer patients with the most suitable therapy for their disease and then track the tumour's progress to see if the treatment is working, according to ...

DNA in blood can track cancer development and response in real time

November 4, 2015
Scientists have shown for the first time that tumour DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment, according to a new Cancer Research UK study published in ...

Estrogen-suppressing drugs substantially reduce breast cancer deaths

July 23, 2015
A class of hormonal drugs called aromatase inhibitors substantially reduce the risk of death in postmenopausal women with the most common type of breast cancer, a major study of more than 30,000 women shows.

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.